Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALI I AMJAD

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1568690287
CMS profile
70704
Location
NEW CASTLE, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$81.08

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $57.15 2
Education $23.93 1

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
AstraZeneca Pharmaceuticals LP $42.87 1
Myovant Sciences Inc. $23.93 1
BeiGene USA, Inc. $14.28 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALI I AMJAD

NPI 1568690287 · CMS profile ID 70704

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

NEW CASTLE, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1568690287?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALI I AMJAD, NPI 1568690287, CMS profile ID 70704. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568690287?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). ALI I AMJAD, NPI 1568690287, CMS profile ID 70704. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568690287?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
ALI I AMJAD, NPI 1568690287, CMS profile ID 70704, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1568690287?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $81.08 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
BeiGene USA, Inc. $14.2810/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940797449 CMS
Myovant Sciences Inc. $23.9307/13/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941176917 CMS
AstraZeneca Pharmaceuticals LP $42.8703/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914897613 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $356.58 4
PY2020 $133.83 1
PY2021 $291.05 6
PY2022 $81.08 3
PY2023 $92.16 4
PY2024 $309.62 9
PY2025 $50.30 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $98,447.15 27
PY2024 Principal investigator $153,570.17 81
PY2023 Principal investigator $135,809.64 30
PY2022 Principal investigator $125,424.34 16
PY2021 Principal investigator $145,880.33 7
PY2020 Principal investigator $158,325.59 8
PY2019 Principal investigator $65,494.13 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

81 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,300.90 12/31/2024 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer No dispute reported 06/30/2026 1155802862
Principal investigator 1 AstraZeneca Pharmaceuticals LP $264.67 12/31/2024 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase III Randomized Multi Center OpenLabel Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum Based Chemotherapy for First Line Treatment in Patients With Metastatic Non Small Cell Lung Cancer NSCLC POSEIDON No dispute reported 06/30/2026 1155804110
Principal investigator 1 BeiGene, Ltd. $2,451.00 12/27/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119726495
Principal investigator 1 BeiGene, Ltd. $52.00 12/16/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119726491
Principal investigator 1 BeiGene, Ltd. $1,000.00 12/16/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119726493
Principal investigator 1 BeiGene, Ltd. $1,000.00 12/11/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119726481
Principal investigator 1 BeiGene, Ltd. $1,872.00 12/11/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119726483
Principal investigator 1 BeiGene, Ltd. $52.00 12/11/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119726485
Principal investigator 1 BeiGene, Ltd. $2,451.00 11/22/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119717355
Principal investigator 1 BeiGene, Ltd. $2,451.00 11/22/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119717357
Principal investigator 1 BeiGene, Ltd. $2,451.00 10/11/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119717149
Principal investigator 1 BeiGene, Ltd. $1,872.00 10/02/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119726355
Principal investigator 1 BeiGene, Ltd. $2,826.00 09/23/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119714539
Principal investigator 1 BeiGene, Ltd. $2,451.00 09/23/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119729520
Principal investigator 1 BeiGene, Ltd. $2,451.00 08/09/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119729512
Principal investigator 1 BeiGene, Ltd. $60.00 08/05/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119714765
Principal investigator 1 BeiGene, Ltd. $118.00 08/05/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119714789
Principal investigator 1 BeiGene, Ltd. $52.00 08/05/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119714805
Principal investigator 1 BeiGene, Ltd. $80.00 08/05/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119723737
Principal investigator 1 BeiGene, Ltd. $52.00 08/05/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119724009
Principal investigator 1 BeiGene, Ltd. $52.00 08/05/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119724059
Principal investigator 1 BeiGene, Ltd. $152.00 08/05/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119724201
Principal investigator 1 BeiGene, Ltd. $1,872.00 07/24/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119714829
Principal investigator 1 BeiGene, Ltd. $2,451.00 07/24/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119723787
Principal investigator 1 BeiGene, Ltd. $2,529.00 07/24/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119723801
Principal investigator 1 BeiGene, Ltd. $1,000.00 07/24/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119729524
Principal investigator 1 GlaxoSmithKline, LLC. $384.83 07/18/2024 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1127539115
Principal investigator 1 BeiGene, Ltd. $66.00 07/15/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119714785
Principal investigator 1 BeiGene, Ltd. $26.00 07/15/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119723795
Principal investigator 1 BeiGene, Ltd. $2,548.00 07/15/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119724193
Principal investigator 1 BeiGene, Ltd. $2,638.00 06/17/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119714387
Principal investigator 1 BeiGene, Ltd. $2,451.00 05/22/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119723347
Principal investigator 1 BeiGene, Ltd. $59.00 05/17/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119714119
Principal investigator 1 BeiGene, Ltd. $109.00 05/17/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119714123
Principal investigator 1 BeiGene, Ltd. $46.00 05/17/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119714211
Principal investigator 1 BeiGene, Ltd. $30.00 05/17/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119723343
Principal investigator 1 BeiGene, Ltd. $40.00 05/17/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119723371
Principal investigator 1 BeiGene, Ltd. $26.00 05/17/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119723373
Principal investigator 1 BeiGene, Ltd. $59.00 05/17/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119723651
Principal investigator 1 BeiGene, Ltd. $26.00 05/17/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119723653
Principal investigator 1 BeiGene, Ltd. $53.00 05/17/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119723661
Principal investigator 1 BeiGene, Ltd. $3,500.00 05/13/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119714361
Principal investigator 1 BeiGene, Ltd. $2,638.00 04/19/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119714235
Principal investigator 1 BeiGene, Ltd. $2,770.00 04/19/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119714241
Principal investigator 1 BeiGene, Ltd. $2,639.00 04/19/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119714355
Principal investigator 1 BeiGene, Ltd. $2,451.00 04/19/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119723345
Principal investigator 1 BeiGene, Ltd. $1,872.00 04/19/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119723619
Principal investigator 1 BeiGene, Ltd. $2,250.00 04/19/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119730621
Principal investigator 1 BeiGene, Ltd. $2,870.00 04/19/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119730651
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,205.00 04/12/2024 Non-covered Recipient Entity
Allegheny Health Network
Phase III 1L Gastric (nivo+ipi vs nivo+CT vs CT) No dispute reported 06/30/2026 1123475786
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,656.15 03/27/2024 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer No dispute reported 06/30/2026 1155804420
Principal investigator 1 BeiGene, Ltd. $1,362.00 03/27/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119726837
Principal investigator 1 BeiGene, Ltd. $1,872.00 03/27/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119730171
Principal investigator 1 BeiGene, Ltd. $4,769.00 03/27/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119730187
Principal investigator 1 BeiGene, Ltd. $450.00 03/27/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119730189
Principal investigator 1 BeiGene, Ltd. $59.00 03/27/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119730191
Principal investigator 1 BeiGene, Ltd. $76.00 03/27/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119730193
Principal investigator 1 BeiGene, Ltd. $30.00 03/27/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119730195
Principal investigator 1 BeiGene, Ltd. $26.00 03/27/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119730197
Principal investigator 1 BeiGene, Ltd. $26.00 03/27/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119730199
Principal investigator 1 BeiGene, Ltd. $40.00 03/27/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119730201
Principal investigator 1 BeiGene, Ltd. $2,705.00 02/27/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119730173
Principal investigator 1 BeiGene, Ltd. $2,451.00 02/27/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119730175
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,000.00 02/21/2024 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) No dispute reported 06/30/2026 1155804096
Principal investigator 1 BeiGene, Ltd. $169.00 02/21/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119717559
Principal investigator 1 BeiGene, Ltd. $33.00 02/21/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119717561
Principal investigator 1 BeiGene, Ltd. $2,548.00 02/21/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119717563
Principal investigator 1 BeiGene, Ltd. $1,000.00 02/21/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119727409
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 02/13/2024 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1127539109
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 02/13/2024 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1127539111
Principal investigator 1 GlaxoSmithKline, LLC. $851.00 02/13/2024 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARL No dispute reported 06/30/2026 1127539113
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $7,268.00 02/06/2024 Non-covered Recipient Entity
Allegheny Health Network
Phase III Study Adj GEJ & Esoph (US EU) (mono) - A Randomized, Multicenter, Double-Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects with Resected Esophageal or Gastroesophageal Junction Cancer No dispute reported 06/30/2026 1123475788
Principal investigator 1 BeiGene, Ltd. $33.00 02/05/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119730145
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,000.00 01/31/2024 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase IB, Open-Label, Randomized, Multi-Center Platform Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Metastatic Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1155804434
Principal investigator 1 BeiGene, Ltd. $337.00 01/26/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119727523
Principal investigator 1 BeiGene, Ltd. $1,672.00 01/26/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119727525
Principal investigator 1 BeiGene, Ltd. $1,872.00 01/26/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119727527
Principal investigator 1 BeiGene, Ltd. $157.00 01/26/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119727529
Principal investigator 1 BeiGene, Ltd. $2,972.00 01/26/2024 Non-covered Recipient Entity
Allegheny Singer Research Institute
A Randomized, Controlled, Open-label, Global Phase 3 Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma No dispute reported 06/30/2026 1119730921
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,807.34 01/10/2024 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy ADRIATIC No dispute reported 06/30/2026 1155804554
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,708.28 01/05/2024 Non-covered Recipient Entity
ALLEGHENY SINGER RESEARCH INSTITUTE
A Phase III Randomized Multi Center OpenLabel Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum Based Chemotherapy for First Line Treatment in Patients With Metastatic Non Small Cell Lung Cancer NSCLC POSEIDON No dispute reported 06/30/2026 1155802486